Insmed ‘Blows Away Expectations’ With Positive Data for Inhaled Hypertension Therapy

Guggenheim Partners called Insmed’s Phase IIb readout “impressive across the board,” with an efficacy profile that positions TPIP to be best-in-class in pulmonary arterial hypertension.